The antibody of this invention is a mouse monoclonal antibody directed against SUMO176-86 recognizing SUMO1 of human, mouse, chicken and X. laevis. It is suitable for western blot and immune precipitation as well as for large-scale enrichment of SUMOylated species by IP / peptide elution.

The invention reveals a method, based on metylation analysis of intragenic regions of the gene DGKA, for estimating the risk of developing radiation induced fibrosis and can therefore be used for therapy planning.

The invention discloses a device that enables bead purification and mixing of the sample without the need for moving the reaction plate from one deck position to the other and hence saving time and deck space.

The Mastomys mouse model is the only existing natural laboratory model to investigate PV pathogenesis and tumor development in the skin, ear, eye and tongue and could help to develop prophylactic or therapeutic approaches to prevent those lesions.

The invention shows that a combination of HDAC and ALK inhibitors for tumortherapy is surprisingly synergistic and can additionally overcome single substance drug resistance.

The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).

The invention discloses an improved version of the chorionallantic membrane, for accurate quantification of metastatic cells in different organs of the chicken embryo at a high sensitivity.

The invention identifies new mutations in the TERT promoter which qualify as diagnostic and prognostic marker.

The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.

Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.

Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.

The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.

The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.

The invention discloses a measles virus based oncolytic tumor therapy. The virus encodes antibodies against CTLA-4 or PD-L1 and has proven effectiveness in a in vivo mouse tumor model.

The antibody recognizes the kinase HIPK2 only when phosphorylated at Thr880 and Ser882 and therefore can be used for predicting kinase activity.

The assembly and maintenance of functional nucleoli is essential for cell viability. DKFZ researchers developed anti-sense oligos that target Alu element-containing RNAs, which are essential for intact nucleoli, for cancer cell specific induction of apoptosis.